Innovative Bispecific Nanobody T Cell Engager Targeting CD3 Complex and PLAUR for Cancer Therapy
VHH-P296 is a domain-based bispecific nanobody harnessing humanized antibody fragments to engage both the CD3 Complex (T Cell Receptor Complex) and plasminogen activator, urokinase receptor (PLAUR). Currently in the Biological Testing stage, VHH-P296 is designed as a promising immunotherapeutic candidate for cancer treatment. By targeting both the CD3 Complex (T Cell Receptor Complex) and PLAUR, VHH-P296 aims to enhance T-cell mediated cytotoxicity within the tumor microenvironment and improve the precision of anti-cancer therapies. Its unique bispecificity has the potential to offer new solutions for cancers that are resistant to conventional therapies.
| Candidate | VHH-P296 |
| Target | CD3 Complex (T Cell Receptor Complex) plasminogen activator, urokinase receptor (PLAUR) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P296 is currently available for out-licensing and collaborative development opportunities. We invite strategic partnerships to advance this innovative bispecific nanobody toward clinical and commercial milestones in cancer immunotherapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P296 |
Modality
VHH-P296 is a next-generation domain-based bispecific T cell engager, featuring a variable heavy chain domain against PLAUR fused to an anti-CD3 single-chain variable fragment. This construct is further linked to an IgG1 Fc region engineered with the LALAPG mutation to optimize immune effector functions and pharmacokinetics. The nanobody's compact single-domain architecture confers benefits such as enhanced tumor penetration and excellent molecular stability, making it especially suitable for targeting dense tumor tissues. Its dual specificity enables the precise redirection of T cells toward cancer cells, offering a mechanistically advanced and flexible approach to cancer immunotherapy.
Target
CD3 Complex and PLAUR are central to the mechanism of VHH-P296. CD3 Complex is a key component of the T cell receptor machinery, primarily expressed on T lymphocytes, and mediates antigen recognition and activation. PLAUR is a surface receptor implicated in cell migration and tissue remodeling, often overexpressed in a variety of malignancies and tumor stroma. Targeting CD3 Complex enables effective recruitment and activation of T cells, while engaging PLAUR redirects immune responses specifically toward tumor cells. The combination of CD3 Complex and PLAUR as targets enhances the selectivity and cytotoxic potential of T-cell engagers. VHH-P296's dual targeting of CD3 Complex and PLAUR represents a strategic advance for immuno-oncology, providing the opportunity to overcome resistance mechanisms and increase treatment specificity.
Mechanism of Action
VHH-P296 functions as a bispecific T-cell engager, simultaneously binding CD3 Complex on T cells and PLAUR present on cancer cells. This dual interaction brings T cells into close proximity with PLAUR-expressing tumor cells, leading to T-cell activation, targeted cytotoxicity, and subsequent tumor cell lysis. By harnessing the nanobody platform, VHH-P296 offers flexible engineering for potential expansion into antibody-drug conjugates or multispecific modalities. The combination of CD3 Complex activation and selective tumor targeting via PLAUR positions VHH-P296 as a promising molecule for driving potent and tumor-specific immune responses, helping to circumvent limitations of conventional single-target immunotherapies.
Cancer
Cancer remains a leading cause of morbidity and mortality worldwide, encompassing a range of heterogeneous diseases characterized by uncontrolled cell growth and metastatic potential. The global cancer burden continues to rise, driven by an aging population and increased exposure to risk factors. Standard treatments include surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapies. However, many patients experience limited response rates, significant toxicity, or eventual disease progression. Tumor heterogeneity and immune escape pose ongoing challenges, leading to a need for innovative therapies that offer better efficacy and specificity. VHH-P296, as a bispecific nanobody T-cell engager, targets critical pathways involved in tumor progression and immune modulation. Its ability to direct T cells to PLAUR-expressing tumor cells introduces a novel approach with the potential to address key gaps in efficacy and safety, supporting improved outcomes for patients with various malignancies.